Lantheus (NASDAQ:LNTH) Price Target Raised to $96.00

Lantheus (NASDAQ:LNTH) had its target price increased by Truist Financial from $82.00 to $96.00 in a report published on Friday, Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

A number of other research firms have also recently weighed in on LNTH. StockNews.com raised Lantheus from a hold rating to a buy rating in a research report on Saturday, January 13th. JMP Securities reaffirmed a market outperform rating and set a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. B. Riley boosted their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research note on Thursday, April 18th. Finally, Mizuho raised their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a buy rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $99.17.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $75.51 on Friday. The company’s fifty day moving average price is $62.82 and its 200 day moving average price is $62.75. Lantheus has a 12 month low of $50.20 and a 12 month high of $100.85. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The firm has a market capitalization of $5.23 billion, a P/E ratio of 11.53 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. As a group, sell-side analysts predict that Lantheus will post 5.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 94,545 shares of company stock valued at $6,169,936. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lantheus

Hedge funds and other institutional investors have recently bought and sold shares of the company. South Dakota Investment Council raised its holdings in Lantheus by 139.3% during the fourth quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock worth $1,694,000 after purchasing an additional 15,900 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new position in Lantheus during the fourth quarter worth $1,385,000. Natixis Advisors L.P. raised its holdings in Lantheus by 172.8% during the third quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock worth $3,649,000 after purchasing an additional 33,273 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Lantheus by 41.9% in the third quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after acquiring an additional 384,093 shares during the last quarter. Finally, Boston Partners raised its holdings in shares of Lantheus by 15.2% in the third quarter. Boston Partners now owns 512,930 shares of the medical equipment provider’s stock worth $35,326,000 after acquiring an additional 67,729 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.